Prospective Grant of Exclusive Patent License: Development of T Cell Receptors (TCRs) Targeting the KRAS G12D Mutation for the Treatment of Cancer, 54817 [2016-19549]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 159 / Wednesday, August 17, 2016 / Notices
additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: August 11, 2016.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–19545 Filed 8–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Advisory Board, September 07, 2016,
09:00 a.m. to September 07, 2016, 5:00
p.m., National Institutes of Health,
Building 31, 31 Center Drive,
Conference Room 10, Bethesda, MD
20892 which was published in the
Federal Register on August 08, 2016, 81
FR 52452.
This meeting notice has been
amended to change the end time of the
open session to 2:45 p.m. The closed
session has also been amended to begin
at 3:00 p.m. and end at 4:15 p.m. The
meeting is partially closed to the public.
Dated: August 11, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–19544 Filed 8–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Development of T Cell
Receptors (TCRs) Targeting the KRAS
G12D Mutation for the Treatment of
Cancer
mstockstill on DSK3G9T082PROD with NOTICES
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Cancer Institute,
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
SUMMARY:
VerDate Sep<11>2014
16:39 Aug 16, 2016
Jkt 238001
an exclusive patent license to Kite
Pharma, Inc. (‘‘Kite’’) located in Santa
Monica, CA to practice the inventions
embodied in the following patent
applications:
Intellectual Property
United States Provisional Patent
Application No. 62/084,654, filed
November 26, 2014, entitled ‘‘Antimutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015/0–US–01];
and
PCT Application No. PCT/US2015/
062269 filed November 24, 2015
entitled ‘‘Anti-mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015/1–PCT–01].
The patent rights in these inventions
have been assigned to the government of
the United States of America. The
prospective exclusive license territory
may be worldwide and the field of use
may be limited to the development,
manufacture and commercialization of
retrovirally-engineered mutated KRAS
TCR-based autologous peripheral blood
T cell therapy products as set forth in
the Licensed Patent Rights for the
treatment of human cancers.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute on or before September 1, 2016
will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Andrew Burke, Ph.D., Licensing and
Patenting Manager, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, MSC 9702,
Rockville, MD 20852; Telephone: (240)
276–5484; Email andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION: The
present invention describes an isolated
T cell receptor (TCR) which recognizes
the G12D mutation of the Kristen rat
sarcoma viral oncogene homolog
(KRAS) protein within the context of
major histocompatibility complex HLA–
A11 presentation.
KRAS is an oncogene with a wellcharacterized role in the formation of
several human cancers, including:
Pancreatic, colorectal and lung. Certain
mutations, such as the substitution of
aspartic acid or valine for glycine at
codon 12 (termed G12D and G12V,
respectively), occur at relatively high
frequency and may represent amenable
targets for immunotherapies. Due to the
restricted expression of KRAS G12D in
pre-cancerous and malignant cells,
engineered T cell therapies based on the
present invention may be useful for the
treatment of select cancers.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
54817
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license may be
granted unless within fifteen (15) days
from the date of this published notice,
the NCI receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in
an appropriate field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: August 8, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2016–19549 Filed 8–16–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Initial Review Group; Neuroscience of
Aging Review Committee.
Date: September 29–30, 2016.
Time: 4:00 p.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: DoubleTree by Hilton Bethesda,
8120 Wisconsin Ave., Bethesda, MD 20814.
Contact Person: Jeannette L. Johnson,
Ph.D., Deputy Review Branch Chief, National
Institutes of Health, National Institute on
Aging, Gateway Building, Bethesda, MD
E:\FR\FM\17AUN1.SGM
17AUN1
]]>Agencies
[Federal Register Volume 81, Number 159 (Wednesday, August 17, 2016)]
[Notices]
[Page 54817]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-19549]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Development of T
Cell Receptors (TCRs) Targeting the KRAS G12D Mutation for the
Treatment of Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Cancer Institute, National Institutes of
Health, Department of Health and Human Services, is contemplating the
grant of an exclusive patent license to Kite Pharma, Inc. (``Kite'')
located in Santa Monica, CA to practice the inventions embodied in the
following patent applications:
Intellectual Property
United States Provisional Patent Application No. 62/084,654, filed
November 26, 2014, entitled ``Anti-mutated KRAS T Cell Receptors'' [HHS
Reference No. E-028-2015/0-US-01]; and
PCT Application No. PCT/US2015/062269 filed November 24, 2015
entitled ``Anti-mutated KRAS T Cell Receptors'' [HHS Reference No. E-
028-2015/1-PCT-01].
The patent rights in these inventions have been assigned to the
government of the United States of America. The prospective exclusive
license territory may be worldwide and the field of use may be limited
to the development, manufacture and commercialization of retrovirally-
engineered mutated KRAS TCR-based autologous peripheral blood T cell
therapy products as set forth in the Licensed Patent Rights for the
treatment of human cancers.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute on or before September 1,
2016 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive license should be
directed to: Andrew Burke, Ph.D., Licensing and Patenting Manager,
Technology Transfer Center, National Cancer Institute, 9609 Medical
Center Drive, MSC 9702, Rockville, MD 20852; Telephone: (240) 276-5484;
Email andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION: The present invention describes an isolated
T cell receptor (TCR) which recognizes the G12D mutation of the Kristen
rat sarcoma viral oncogene homolog (KRAS) protein within the context of
major histocompatibility complex HLA-A11 presentation.
KRAS is an oncogene with a well-characterized role in the formation
of several human cancers, including: Pancreatic, colorectal and lung.
Certain mutations, such as the substitution of aspartic acid or valine
for glycine at codon 12 (termed G12D and G12V, respectively), occur at
relatively high frequency and may represent amenable targets for
immunotherapies. Due to the restricted expression of KRAS G12D in pre-
cancerous and malignant cells, engineered T cell therapies based on the
present invention may be useful for the treatment of select cancers.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404. The prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the NCI
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in an appropriate field of use
that are timely filed in response to this notice will be treated as
objections to the grant of the contemplated exclusive license. Comments
and objections submitted to this notice will not be made available for
public inspection and, to the extent permitted by law, will not be
released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: August 8, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2016-19549 Filed 8-16-16; 8:45 am]
BILLING CODE 4140-01-P
